April 2026 in “International Journal of Nanomedicine” Quercetin delivery systems are improving its effectiveness for medical use.
4 citations
,
April 2025 in “Scientific Reports” Platelet-rich plasma can temporarily inhibit some drug-resistant bacteria in diabetic foot infections.
May 2023 in “Asian journal of research in pharmaceutical sciences” Ketoconazole is effective for treating various fungal infections and has new uses in dermatology, but oral use can have serious side effects.
March 2022 in “International Journal of Health Sciences” Pentoxifylline helps hair regrowth in rats with hair loss.
1 citations
,
November 2024 in “Neuro-Oncology” Temozolomide can cause severe bone marrow suppression, leading to life-threatening complications.
3 citations
,
January 2025 in “Scientific Reports” Cepharanthine is safe but not effective in significantly reducing COVID-19 recovery time.
24 citations
,
October 2008 in “International Braz J Urol” Lovastatin doesn't improve lower urinary tract symptoms treatment.
June 2019 in “Reactions Weekly” 9 citations
,
October 2015 in “Cutaneous and ocular toxicology” Vemurafenib can cause scalp issues but can be managed without changing the dose.
5 citations
,
February 2024 in “Clinical Pharmacokinetics” A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
January 2019 in “Research & Reviews: Journal of Pharmaceutics and Nanotechnology” Nanotechnology can effectively deliver antimicrobial peptides for treating infections.
1 citations
,
September 2025 in “The Oncologist” Effective management of side effects is crucial for safe use of sacituzumab govitecan in advanced breast cancer treatment.
April 2018 in “Journal of Investigative Dermatology” May 2023 in “Zenodo (CERN European Organization for Nuclear Research)” March 2026 in “Journal for ImmunoTherapy of Cancer” Long-term data and a team approach are needed to manage chronic side effects from cancer treatments.
40 citations
,
December 2016 in “Journal of Dermatological Treatment” JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.
June 2025 in “BMJ Case Reports” Axitinib treatment turned a man's grey hair back to black.
January 2016 in “Chemistry & Industry” Two drugs, tofacitinib and ruxolitinib, may help regrow hair by activating hair follicles.
12 citations
,
April 2023 in “Molecular Pharmaceutics” A new patch can deliver stable antibodies over time for potential HIV treatment.
24 citations
,
July 2013 in “Oncologist” Bendamustine combined with rituximab is an effective and well-tolerated treatment for certain types of lymphoma.
5 citations
,
January 2021 in “Indian Journal of Pharmacology” Nilotinib can cause generalized keratosis pilaris.
3 citations
,
May 2023 in “Clinical drug investigation” JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
15 citations
,
January 2016 in “Dermatologic Clinics” Start acne treatment early to prevent scarring, consider antibiotic resistance, use maintenance therapy, and manage side effects carefully.
April 2011 in “Reactions Weekly”
12 citations
,
November 2014 in “Journal of Cutaneous Medicine and Surgery” Antiviral medication valganciclovir may improve skin and hair in Trichodysplasia Spinulosa patients.
3 citations
,
February 2005 in “Lung Cancer” The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.
January 2012 in “Chinese Clinical Oncology” Disodium folinate can safely and effectively replace calcium folinate in colorectal cancer treatment.
6 citations
,
August 2013 in “Joint Bone Spine” Tocilizumab treatment was associated with significant hair regrowth in one patient and temporary hair loss followed by regrowth in another.
15 citations
,
December 2020 in “Pharmacology Research & Perspectives” Blocking enzymes that help the virus enter cells could be a promising way to treat COVID-19.
September 2025 in “International Journal of Molecular Sciences” Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.